CMR2009: 7.04: Exploitation of necrosis avidity: from diagnostics to theragnostics in oncology

✍ Scribed by Y. Ni; J. Li; M. M. Cona; F. Chen; H. Wang; T. Marysael; P. de Witte; K. Prinsen; A. Verbruggen; G. Bormans; L. Zhou; J. Nuyts; G. Marchal; J. Zhang; Z. Sun

• Publisher: John Wiley and Sons
• Year: 2009
• Tongue: English
• Weight: 259 KB
• Volume: 4
• Category: Article
• ISSN: 1555-4309
• DOI: 10.1002/cmmi.335

✦ Synopsis

state. The same protocol was followed for EL4 tumor-bearing mice 24 h after treatment with etoposide. Results: A comparative study was performed between hyperpolarized 1-13 C pyruvate, and 1,4-13 C 2 fumarate in a mouse EL-4 lymphoma model. The substrates 1,4-13 C 2 fumarate and 1-13 C pyruvate both peak at the same time approximately 8 s after injection. The metabolites 1,4-13 C 2 malate and 1-13 C lactate on the other hand peak at 30 and 15 s, respectively. The optimal tracer concentration was found to be 20 mM and the SNR and contrast study were performed at this concentration. For each substrate the optimal time was used to acquire the CSI. The average SNR was 10.8 and 36.4 for 1,4-13 C 2 malate and 1-13 C lactate, respectively. The contrast was determined to be 7.2 and 4.9 for 1,4-13 C 2 malate and 1-13 C lactate, respectively. Fumarate was used as a therapy marker in this model. Contrary to pyruvate, fumarate showed a 2.4-fold increase in the malate production in treated vs non-treated mice.

Conclusion:

We show that the conversion of 1,4-13 C 2 fumarate to 1,4-13 C 2 malate has comparable imaging qualities to the well-known substrate/metabolite pair 1-13 C pyruvate/1-13 C lactate in this model. In a cancer treatment study 1,4-13 C 2 -fumarate gives rise to a positive contrast, which favors this marker as a diagnostic tool.